Affinity maturation of a novel antagonistic human monoclonal antibody with a long V_H CDR3 targeting the Class A GPCR formyl-peptide receptor 1

Julie A DouthwaiteMedImmune Ltd.; Cambridge, UKCorrespondence[email protected]

Sudharsan SridharanMedImmune Ltd.; Cambridge, UK

Catherine HuntingtonMedImmune Ltd.; Cambridge, UK

Jayne HammersleyMedImmune Ltd.; Cambridge, UK

Rose MarwoodMedImmune Ltd.; Cambridge, UK

Jonna K HakulinenDiscovery Sciences; Structure, Biophysics and Computational Sciences; AstraZeneca R&D; Mölndal, Sweden

Margareta EkDiscovery Sciences; Structure, Biophysics and Computational Sciences; AstraZeneca R&D; Mölndal, Sweden

Tove SjögrenDiscovery Sciences; Structure, Biophysics and Computational Sciences; AstraZeneca R&D; Mölndal, Sweden

David RiderEmployees of MedImmune Ltd. at the time the work was undertaken

Cyril PrivezentzevEmployees of MedImmune Ltd. at the time the work was undertaken

Jonathan C SeamanMedImmune Ltd.; Cambridge, UK

Peter CariukMedImmune Ltd.; Cambridge, UK

Vikki KnightsEmployees of MedImmune Ltd. at the time the work was undertaken

Joyce YoungEmployees of MedImmune Ltd. at the time the work was undertaken

Trevor WilkinsonMedImmune Ltd.; Cambridge, UK

Matthew SleemanMedImmune Ltd.; Cambridge, UK

Donna K FinchMedImmune Ltd.; Cambridge, UK

David C LoweMedImmune Ltd.; Cambridge, UK

Tristan J VaughanMedImmune Ltd.; Cambridge, UK

Your download is now in progress and you may close this window